STOPDAPT-2 Risk Subgroup Calculator

Clinical calculation support · Verify results before clinical use

Patient subgroup context

Record relevant clinical features to review the evidence context. This tool does not calculate an individual event probability.

Evidence context

Recorded for clinical context only; age is not part of a validated STOPDAPT-2 subgroup risk equation.

Context only
Acute coronary syndrome (ACS) presentation?

The STOPDAPT-2 ACS trial specifically studied patients presenting with ACS.

High bleeding risk (HBR) criteria met?

Use a recognized definition such as ARC-HBR when making the clinical classification.

Complex PCI?

Use the study's procedural definition where applicable; complexity should not be inferred from this selection alone.

Interpretation status

No subgroup review yet

Select the available clinical features and choose “Review subgroup context.” The tool will summarize relevant evidence without generating an unsupported risk percentage.

Clinical context

STOPDAPT-2 subgroup characteristics are not a validated individual prediction model. The result is an evidence summary, not a treatment recommendation.

Do not use this tool alone to determine DAPT duration. Individual ischemic and bleeding risks, procedural details, patient preferences, and current guidelines require clinician assessment.

About STOPDAPT-2 ACS

STOPDAPT-2 ACS compared clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy (DAPT) with 12-month DAPT in patients with ACS undergoing PCI. The abbreviated strategy did not meet the prespecified criterion for noninferiority for the primary composite endpoint.

Reported 1-year outcomes in STOPDAPT-2 ACS

Outcome1–2-month DAPT12-month DAPTEffect estimate
Primary composite endpoint3.2%2.8%HR 1.14 (95% CI 0.80–1.62); noninferiority P=.06
Cardiovascular endpoint2.7%1.9%HR 1.50 (95% CI 0.99–2.26)
TIMI major/minor bleeding0.5%1.2%HR 0.46 (95% CI 0.23–0.94)

These are trial-arm event rates, not individualized predictions and not outputs calculated from the selected patient characteristics.

How to interpret subgroup features

  • ACS: the ACS-specific randomized trial did not establish noninferiority of the abbreviated DAPT strategy for its primary endpoint.
  • HBR and complex PCI: these are clinically important dimensions of DAPT decision-making. Published subgroup analyses do not justify multiplying a generic baseline risk by arbitrary factors to produce an individual event probability.
  • Age: age is relevant to overall clinical assessment but is not an input to a validated STOPDAPT-2 risk equation in this tool.

References

Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiology. 2022;7(4):407–417. doi:10.1001/jamacardio.2021.5244.
Yamamoto K, et al. Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI. JACC: Asia. 2023;3(1):31–46. doi:10.1016/j.jacasi.2022.09.011.
STOPDAPT-2 trial investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA. 2019. Full text (PubMed Central).
Clinical disclaimer: This is an educational evidence-context tool, not a validated risk calculator and not a substitute for guideline-based clinical judgment. It does not estimate individual ischemic events, bleeding events, or net composite risk. Confirm patient-specific decisions against current guidance and the full clinical picture.